PRS 211092

Drug Profile

PRS 211092

Alternative Names: PRS 211092-000

Latest Information Update: 28 Jul 2009

Price : $50

At a glance

  • Originator Pharmos Corporation
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 13 Jun 2006 No development reported - Preclinical for Stroke in USA (unspecified route)
  • 15 Jan 2003 PRS 211092 is available for licensing [www.pharmoscorp.com]
  • 21 Oct 2002 Preclinical trials in Stroke in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top